Document is current
Any future updates will be listed below
-
Authors
Wang, Yu
Zhang, Jing
Fan, Meiyang
Hou, Xianbin
Li, Xiaomeng
Zhang, Wentao
Liu, Wenbin
Li, Yue
Lu, Yaqi
Li, Fei https://orcid.org/0000-0002-2409-9282
Guan, Yanglong
Wang, Yudan
Yuan, Bingyu
Li, Xiaowei
Gong, Huilin
Ning, Feng
Zhuo, Xiaozhen
Lu, Shemin https://orcid.org/0000-0001-8250-850X
Meng, Liesu https://orcid.org/0000-0003-1985-050X
Holmdahl, Rikard https://orcid.org/0000-0002-4969-2576
Zhu, Wenhua https://orcid.org/0000-0002-2820-2427
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82171724，82370460)
National Natural Science Foundation of China (82372900)
National Natural Science Foundation of China (82471830, W2431021)
Natural Science Foundation of Shaanxi Province (2025JC-JCQN-096)
Natural Science Foundation of Shaanxi Province (2024JC-YBQN-0773)
Natural Science Foundation of Shaanxi Province (2025JC-YBMS989)
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 23 March 2026
First Online: 8 April 2026
Competing interests
: The authors declare the following competing interests: A patent application related to the application of CHI3L2 neutralizing antibody in inflammatory diseases has been filed with the China National Intellectual Property Administration by Xi’an Jiaotong University, with WH.Z., F.L., Y.W., L.M., S.L., R.H., and WT.Z. as inventors (application number CN 202511780768.X). The remaining authors declare no competing interests.
